- Home
- AUST vs CELU Comparison
AUST vs CELU Comparison
Compare AUST & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | CELU |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 17.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AUST | CELU |
|---|---|---|
| Price | $1.31 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 134.8K | 35.0K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $26,550,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $0.56 |
| 52 Week High | $3.92 | $4.30 |
Technical Indicators
Market Signals| Indicator | AUST | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 49.43 |
| Support Level | $1.27 | $0.69 |
| Resistance Level | $1.42 | $0.85 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 94.12 | 63.16 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration, and evaluation of mineral resource properties in the western United States of America (USA). The exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek, Lone Mountain, Stockade Mountain, Fourmile Basin, and Miller.
About CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.